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Presence of myocardial fibrosis in well-established non-ischaemic dilated cardiomyopathy 
(NIDCM) is associated with adverse clinical outcomes. However, the impact of myocardial 
fibrosis at first presentation in NIDCM, and its long-term association with left ventricular (LV) 
dysfunction, heart failure (HF) and ventricular arrhythmia (VA) remains unclear. We 
investigated whether the presence of myocardial fibrosis quantified by late gadolinium 
enhancement cardiovascular magnetic resonance (LGE-CMR) at presentation, is 
independently associated with long term major adverse cardiovascular events (MACE) in 
patients with first presentation NIDCM. 
Methods 
Consecutive patients with a first diagnosis of NIDCM were recruited. Patients underwent LGE-
CMR at baseline. Replacement myocardial fibrosis by LGE-CMR was quantified by 
experienced observers blinded to patient outcome. MACE was defined as a composite end-
point including cardiac death, HF rehospitalisation and the occurrence of sustained VA. 
Results  
Fifty-one patients with first presentation NIDCM were included, of which 49 (96%) had follow 
up and outcome data. Median follow up was 8.2 years. Both the LGE positive and LGE 
negative groups had similar clinical characteristics at follow up. In univariate Cox regression 
analysis, positive LGE was associated with MACE (HR:3.44; 95% CI:1.89 to 6.24, p-
value<0.001) and HF rehospitalisation (HR:2.89; 95% CI:1.42 to 5.85, p-value=0.003). In 
multivariate Cox regression, positive LGE-CMR was independently associated with MACE 
(HR:3.53; 95% CI:1.51 to 8.27, p-value=0.004) and HF rehospitalisation (HR:3.07; 95% 


















The presence of myocardial fibrosis in first presentation NIDCM is independently associated 



















Non-ischaemic dilated cardiomyopathy (NIDCM) is characterised by impairment in systolic 
left ventricular (LV) function following a non-ischaemic, mechanistically variable but often 
poorly defined, myocardial insult. Clinical management of this condition is generally 
determined by the patient’s symptoms, the electrocardiogram and the LV ejection fraction 
(LVEF) on echocardiogram. This approach has limitations in specifically identifying patients 
who are unlikely to respond to medical therapy or who are at higher risk of sudden cardiac 
death (1). This is graphically displayed in a study of 8000 patients with ischaemic and non-
ischaemic cardiomyopathy and LVEF <40%, which demonstrated that despite the use of 
modern therapies, there is a 20% mortality rate at 2 years (2).  
 
Over the last two decades cardiovascular magnetic resonance (CMR) has been utilised in the 
diagnostic assessment of patients with NIDCM. Late gadolinium enhancement cardiovascular 
magnetic resonance (LGE-CMR) has shown that ≈30% of patients with established NIDCM 
have mid-wall LGE, which represents replacement fibrosis, and that this provides incremental 
prognostic information to LVEF (3). In particular, multiple studies have shown that the 
presence of LGE-CMR in the NIDCM population portends to increase risk of heart failure 
events, ventricular arrhythmias (VA) and sudden cardiac death (SCD) (4, 5).  
 
All previous studies have focused on patients with established NIDCM for a duration of at least 
6 months. Whether mid-wall LGE identifies high risk patients at their first presentation 
NIDCM, is unknown. Using a unique cohort of patients with first presentation NIDCM, we 
have previously demonstrated that the presence of mid-wall LGE at presentation leads to 
adverse LV remodeling at 5 months (6). Whether this is associated with adverse clinical 
















presentation NIDCM with LGE-CMR is associated with major adverse clinical events (MACE) 
over a long term follow up. We hypothesized that the presence of myocardial fibrosis as 
detected by LGE-CMR in patients at their first presentation of NIDCM would be independently 
associated with MACE. 
 
METHODS 
Study population and protocol 
The details of the subject characteristics, inclusion and exclusion criteria have been previously 
reported (6). In summary, consecutive patients were recruited from 3 university hospitals where 
they had presented with new onset heart failure (HF) with NIDCM diagnosed after routine 
clinical, echocardiography and coronary angiography work-up. The inclusion criterion was the 
presence of LV ejection fraction ≤45% at baseline echocardiography or CMR. Exclusion 
criteria included the diagnosis of significant coronary artery disease (defined as >70% luminal 
stenosis in an epicardial coronary artery at angiography, non-invasive stress imaging 
suggestive of ischemia, or prior myocardial infarction), severe valvular heart disease, thyroid 
dysfunction, infiltrative cardiomyopathy or extra-cardiac systemic features to suggest 
sarcoidosis or amyloidosis, chemotherapy-induced cardiomyopathy, hypertrophic 
cardiomyopathy, peripartum cardiomyopathy, alcohol-induced cardiomyopathy and 
myocarditis. Myocarditis was excluded by the absence of classic clinical features, the presence 
of normal serum troponin I concentration at presentation, and by the lack of evidence of 
myocardial oedema on T2-weighted CMR (7). Patients were excluded from CMR when renal 
impairment (eGFR <60mL/min), or other conventional CMR contra-indications were present. 
HF therapies were administered in accordance with the 2008 European Society of Cardiology 

















Research LGE-CMR and transthoracic echocardiography was performed within two weeks of 
presentation with first diagnosis NIDCM when clinically stable. To minimise variability due 
to loading conditions, CMR and echocardiography were performed in immediate succession 
for each individual. All patients provided written and informed consent to the study which was 
approved by the relevant Human Research Ethic Committee. 
 
Cardiac Magnetic Resonance Protocol and Analysis 
The full protocol has been described elsewhere (6); in brief, CMR was performed using 
commercially available 1.5T machines (Siemens Avanto, Erlangen, Germany or Philips Intera, 
Best, The Netherlands). Electrocardiographically-gated steady-state free precession imaging 
of the LV in the short-axis plane was undertaken. LGE-CMR imaging was undertaken 10 
minutes following intravenous administration of gadolinium-DTPA 0.1mmol/kg using an 
inversion-recovery segmented gradient echo sequence. CMR data analysis was performed by 
2 experienced (SCMR Level 3) observers, using commercially available software (CAAS 
MRV Version 3.3, PIE, Netherlands) (6, 9). Any disagreements were adjudicated by a third 
observer. 
 
Clinical Outcomes Data 
The primary study endpoint was the total number of MACE. MACE was defined as the 
composite of cardiac death, acute unplanned HF hospitalisation and the occurrence of 
ventricular arrhythmia (VA). VA events are defined as nonfatal ventricular fibrillation (VF), 
sustained ventricular tachycardia (VT) requiring external cardioversion or appropriate therapy 
by implantable cardioverter defibrillator (ICD) device triggered by VF or VT. VA that occurred 
during acute HF hospitalisations or leading to sudden cardiac death was not included and was 
















valvular disease or myocardial infarction) in the interim period was obtained annually from the 
outpatient follow up clinical notes. Outcome, clinical events and mortality data were obtained 
from a state-wide hospital database with clinical information coded according to the 
international classification of diseases. Adjudication was made by two physicians blinded to 




All analysis was performed in Stata version 14.2 (StataCorp, College Station, Texas, USA). 
The association of LGE was separately assessed on overall mortality, overall MACE (cardiac 
death, HF hospitalisation or VT/VF) and each type of MACE using log-rank analysis, 
univariate and multivariate Cox regression. Subjects were followed from their date of 
enrolment until the end date of the study (31st October 2017) or until the date of death if this 
was earlier. Subjects with more than one MACE continued in the study so that multiple events 
per subject were possible. Standard errors were adjusted for within-subject correlation using 
the cluster(id) vce(robust) option in Stata. For each of the outcomes, univariate Cox regression 
was used to test for unadjusted associations. Then, variables that were significant at p<0.20 
were entered into a multivariate Cox regression model. For consistency across outcomes, age 
and RV ejection fraction (RVEF) were included as adjustment variables in all models as these 
were each significant (p<0.05) at the univariate level for MACE (all events). The assumption 
of proportional hazards for the overall model and LGE variable alone were tested using the 
proportional hazards test based on the Schoenfeld residuals. The effect of LGE was considered 
significant when p<0.05. The estimated survival rates by LGE status was shown using 
















association with LGE and each non-mortality outcome (VT/VF, rehospitalisation and all 




Follow up data were available in 49 (96%) patients. Table 1 shows the clinical characteristics 
of these patients. Seventeen (35%) patients had myocardial fibrosis (LGE positive) at baseline 
CMR. LGE was found in the mid-wall or at the insertion point of the right ventricular free wall 
and the interventricular septum. No ischaemic pattern of LGE was observed in this cohort. In 
total there was cumulative follow up of 321 years. Both the LGE positive and LGE negative 
groups were well matched for age, sex, rhythm and QRS duration, as well as baseline 
echocardiography and CMR variables prior to study enrolment (Table 1a). At follow up 
(median time 72 months for LGE positive group and 75 months for LGE negative group) there 
was no difference in echocardiographic LVEF (p=0.756) and no new development of 
significant valvular heart disease or myocardial infarction. Seven patients (five LGE positive) 
had ICD implanted for primary prevention while two patients (one LGE positive) for secondary 
prevention. In addition, no significant difference in HF medication (loop diuretics, beta-
blockers, angiotensin-converting enzymes or angiotensin receptor blockers (ACEi/ARB) and 
mineralocorticoid receptor antagonist (MRA)) was noted between the LGE positive and LGE 
negative groups (Table 1b). 
 
Myocardial Fibrosis (positive LGE CMR) and Outcomes.  
Patients were followed-up for a median duration of 8.2 years (interquartile range 7.1 – 9.1 
years) with a maximum follow up of 9.4 years. The presence of myocardial fibrosis was 
















events occurred amongst 10 of 17 patients (59%) with LGE and 17 MACE events in 10 of 32 
patients (31%) without LGE. On Kaplan-Meier analysis, LGE was associated with a higher 
occurrence of MACE (log-rank p = <0.001) (Figure 1a). Within this composite end point, a 
total of 19 recorded HF hospitalisations occurred in 9 of 17 patients (53%) with LGE and 13 
HF hospitalisation events in 7 of 32 patients (22%) without LGE. In patients with multiple HF 
rehospitalisation events, the median duration between each acute rehospitalisations was 337 
days. On Kaplan-Meier analysis, LGE was associated with HF hospitalisation (log-rank p = 
0.002) (Figure 1b). Moreover, there were 9 documented VA events in 3 of 17 patients (18%) 
with LGE in contrast to 2 VA events in 2 of 32 patients (6%) without LGE. On Kaplan-Meier 
analysis, LGE was associated with increased VA events (log-rank p = 0.001) (Figure 1c). Both 
positive and negative LGE group had 2 patients with cardiac mortality. In the group with LGE 
the 2 cardiac deaths were due to sudden cardiac death. In the group without LGE, one patient 
died of sudden cardiac death and the other died of myocardial infarction. The presence of LGE 
was not associated with increased cardiac mortality (log-rank p = 0.47) (Figure 1d).  
 
In Cox regression analysis (Table 2a), the independent variables considered for inclusion into 
the model in addition to LGE were age, QRS duration, atrial fibrillation (AF), N-terminal pro-
brain natriuretic peptide (NT-pro-BNP), echocardiography and CMR parameters. In univariate 
analysis Cox regression analysis, LGE was predictive of MACE (HR: 3.44; 95% CI: 1.89 to 
6.24, p-value < 0.001), HF hospitalisation (HR: 2.89; 95% CI: 1.42 to 5.85, p-value = 0.003) 
and VA events (HR: 8.4; 95% CI: 1.81 to 39.7, p-value = 0.007) (Table 2b). Variables with 
p<0.20 were included in the multivariate cox regression model (Table 2a). LGE was 
significantly and independently associated with total MACE (HR: 3.53; 95% CI: 1.51 to 8.27, 
p-value = 0.004) and HF hospitalisation (HR: 3.07; 95% CI: 1.24 to 7.59, p-value = 0.015) but 
















In the sensitivity analysis using the first event for each patient only, the multivariate hazard 
ratio was reduced for MACE (HR=2.22, p=0.0168 versus HR=3.53, p=0.004) but almost 
identical for HF rehospitalisation (HR=3.22, p=0.069 versus HR=3.07, p=0.015). The analysis 
for first VA event was identical since all of the subjects included in the previous analysis had 
only 1 event (41 subjects of whom 3 had 1 VT/VF). The smaller number of events in the 
sensitivity analysis of MACE (14 versus 30) resulted in much wider confidence intervals for 

















This study shows that LGE in patients at first presentation with NIDCM is independently 
associated with increased heart failure rehospitalisation for almost a decade after diagnosis. 
Heart failure events are associated with the presence of essentially pre-diagnosis replacement 
myocardial fibrosis, thereby representing a group who may warrant more aggressive therapy 
and intensified follow up. This is evident with a recent study demonstrating that the presence 
of myocardial fibrosis predicts unfavourable long term survival in heterogeneous population 
of new-onset of HF (10). Additionally, our findings increase the clinical impetus for aggressive 
management of patients at risk of heart failure or those with asymptomatic left ventricular 
dysfunction where the syndrome of chronic heart failure has not yet evolved. Our study further 
highlights the long-term implications of myocardial fibrosis in a well described population with 
first presentation NIDCM.  
 
We found that the presence of mid-wall LGE on the presentation CMR scan (performed within 
the first 2 weeks after clinical presentation) was independently associated with MACE, being 
driven mainly by a higher rate of HF hospitalisations. It is likely that this observation is 
explained by reduced reverse remodelling to HF treatment in patients having LGE, as 
demonstrated in our previous study of the same cohort (6). Our unique, prospective, 
longitudinally followed cohort study links presentation mid-wall LGE and the lack of 
echocardiographic LVEF improvement at 5 months to long term MACE, comprising mainly 
of HF hospitalisation’s. Importantly, while NIDCM presentation can occur at any age, most 
patients are first seen between ages 20 and 50 years (11), thereby magnifying the potential 

















Initial studies focusing on patients with established NIDCM of at least 12 months duration have 
demonstrated that LGE was the sole independent predictor of cardiovascular hospitalisation 
and death (12, 13). In the largest study to date, Halliday et al reported a remarkably similar 
prevalence of LGE of 34.3% (14). This study of 874 patients with NIDCM demonstrated that 
patients with myocardial fibrosis on LGE are more likely to have significant VA events and 
death (14). The same group prospectively studied patients with NIDCM with an LVEF 40% 
and demonstrated an increased risk of SCD in patient with presence of LGE (15). A recent 
meta-analysis has validated the presence of myocardial fibrosis detected via LGE-CMR in 
NIDCM as an independent predictor of MACE (HR 2.88; p<0.001) and VA/SCD (HR 4.32; 
p<0.001) (16). 
 
The association of HF hospitalisation with LGE in first presentation NIDCM may largely 
reflect the relative frequency of this endpoint, however the independent association with a 
marker of symptomatic heart failure needs to be acknowledged and is potentially 
mechanistically instructive. NIDCM is generally a global pathogenic process. Autopsy data 
has shown the substrate for diffuse fibrosis is perivascular and interfibre fibrosis (17). 
Furthermore, the pressure-volume overload and wall stress would lead to compensatory 
process that mainly affects the middle circumferential myocardial layer (18, 19). Hence mid-
wall LGE could potentially represent the final pathway of these aforementioned patho-
physiological mechanisms (20). Recent advancements in CMR parametric T1 mapping 
techniques which were not available at study enrolment, enables the quantitative assessment of 
diffuse myocardial fibrosis (21, 22). This technique has demonstrated that besides the presence 
of LGE, the abnormalities in native T1 times are independent markers of all-cause mortality, 

















Whilst the prior studies looked at patients with established NIDCM, our study focused on the 
long-term outcome of consecutive patients with first presentation NIDCM. We found a 
remarkably similar incidence of LGE at NIDCM presentation (35%) to the vast literature on 
established NIDCM (12-14). This essentially represents “pre-diagnosis” fibrosis highlighting 
the significant duration of pre-clinical disease in NIDCM and providing impetus for study of 
preventative therapy in high risk subgroups (e.g. genotypic positive familial cardiomyopathy 
carriers). These findings have potential important clinical implications. A reliable early marker 
of poor outcome as well as both heart failure and ventricular arrhythmic events could be used 
to rationalise early and intensified treatment to patients most in need. Previous animal models 
have shown that angiotensin II receptor blocker neprilysin inhibitor (ARNI) have attenuating 
effects on cardiac fibrosis and cardiac remodelling (24, 25). Hence, this could potentially 
reverse or blunt the progression of first presentation or even at risk NIDCM – an important 
direction for future research, in which hard clinical endpoints might be examined.  
 
It is increasingly recognised that myocardial scar induced re-entry arrhythmias make up the 
majority of VA in the cardiomyopathic heart (26, 27). Intuitively, scar represented by LGE 
would be expected to be mechanistically associated with VA events. The lack of independent 
association between LGE and life-threatening VA seen in our study, goes against prior findings 
in established NIDCM. This could be explained by the low number of patients or the low 
number of VA event observed in this observational study. Present day guidelines recommend 
primary prevention ICD implantation in NIDCM for those with LVEF <35% (28, 29). 
However, the majority of patients who succumb to SCD have LVEF > 35%, hence, our tools 
of risk stratifying these patients for likelihood of SCD are poor (30). Furthermore, Kober et al 
have recently demonstrated that ICD implantation guided solely by LVEF may not confer a 
















currently underway to answer the question of whether a CMR guided approach is superior to 
standard care in NIDCM patients with mild-moderate systolic dysfunction (32) and myocardial 
fibrosis, LGE-CMR has already shown utility in guiding implantation of cardiac 
resynchronisation therapy (CRT) devices (33, 34). In addition CRT with defibrillation (CRT-
D) has been shown to be superior to CRT in non-ischaemic cardiomyopathy patients with 
myocardial fibrosis on LGE-CMR (35). 
 
Study Limitations 
Our study has some limitations. Firstly, it is observational in nature and hence there may have 
been residual confounding due to differences in length of patient symptoms, patient 
characteristics and disease course prior to diagnosis that were not measured. In addition, the 
study was relatively small and there were only a small number of specific events, although the 
total number was similar to those observed in larger studies. Still a larger study could provide 
better understanding into patient symptoms and characteristics which may be clinically 
relevant. The low uptake of ACEi/ARB could confound this further. However, it could reflect 
the current clinical uncertainty on how the long term management of these patients should be. 
While the significant associations that were observed cannot have been underpowered, the low 
number of events for VA and mortality will have reduced the power for determining predictive 
capacity of LGE-CMR for these events. In addition there is a notable lack of a 
univariable association between outcomes and NTproBNP, LAVi and CMR LVEF which is 
likely due to the study being under powered. Similarly, although hazard ratios were similar for 
MACE and acute HF rehospitalisation, when we used first events only in the sensitivity 
analysis, the smaller number of events reduced our power still further. However, assuming that 
the point estimate for our observed effect were retained in future larger studies, a dataset with 
















association. In contrast, strengths of the study include its long follow up (to the best of our 
knowledge the longest study of this type), the well described population, and immediate 
follow-up after presentation allowing a unique, prospective, longitudinal link between LGE-
CMR and HF rehospitalisation. 
 
CONCLUSION 
The presence of myocardial replacement fibrosis as detected by CMR-LGE is independently 
associated with an increased risk of HF rehospitalisation in first presentation NIDCM. This 
finding has potential therapeutic implications in the heart failure management of patients with 
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Figure 1a: Positive LGE was associated with higher MACE 
 

















Figure 1c: Positive LGE was associated with higher VA 
 
 
















Table 1a: Characteristics of NIDCM patients at baseline. 
Characteristics LGE Positive (N=17) LGE Negative 
(N=32) 
P-value 
Age (years) 61 (54-67) 57 (49-66) 0.475 
Male gender, n (%) 13 (76%) 22 (69%) 0.724 
AF, n (%) 5 (29%) 7 (22%) 0.589 
QRS duration (ms) 118 (94-142) 97 (82-111) 0.115 
Median NT-pro 
BNP (ng/l) 
720 (609-2870) 683 (446-3718) 0.771 
Baseline ECHO 
LVEF (%) 
29 (24-33) 29 (24-34) 0.98 
ECHO LAVi 40 (29-50) 38 (29-47) 0.769 
CMR LVEF (%) 20 (15-26) 26 (23-30) 0.057 
CMR LV EDVi 
(ml/m2) 
121 (94-147) 107 (90-124) 0.3796 
CMR LV ESVi 
(ml/m2) 
94 (72-115) 78 (64-92) 0.205 
CMR LV Mass 
Index (g/m2) 
69 (53-86) 78 (64-92) 0.409 
CMR RVEF (%) 38 (27-49) 45 (39-51) 0.283 
CMR RV EDVi 
(ml/m2) 
64 (48-79) 63 (52-73) 0.925 
CMR RV ESVi 
(ml/m2) 

















Legend: AF = atrial fibrillation, NT-pro BNP = N-terminal pro-brain natriuretic peptide, LGE 
= late gadolinium enhancement, ECHO = echocardiogram, LAVi = left atrial volume index, 
LVEF = left ventricular ejection fraction, RVEF = right ventricular ejection fraction, EDVi = 
end-diastolic volume index, ESVi = end-systolic volume index, ACEi = angiotensin converting 
enzyme inhibitor, ARB = angiotensin receptor blocker  
 
Table 1b: Characteristics of NIDCM patients at follow-up. 
Characteristics LGE Positive (N=17) LGE Negative 
(N=32) 
P-value 
Follow up ECHO 
LVEF (%) 
(Median time to 








Frusemide (%) 43 % 47 % 0.867 
Beta-blocker (%) 86 % 87 % 0.952 
ACEi/ARB (%) 57 % 73 % 0.448 
Spironolactone (%) 57 % 67 % 0.665 
Sacubitril/Valsartan 
(%) 
14 % 0 % 0.98 
 
Legend: ECHO = echocardiogram, LVEF = left ventricular ejection fraction, ACEi = 















Table 2a: Cox Regression Analyses for MACE 
Variable 
Univariate Multivariate * 
HR (95% CI) p-value HR (95% CI) p-value 
LGE 
Age (years) 




CMR LVEF (%), per 1 SD 
CMR LV EDVi (ml/m2) , per 1 SD 
CMR LV ESVi (ml/m2) , per 1 SD 
CMR LV Mass Index (g/m2) , per 1 SD 
CMR RVEF (%), per 1 SD 
CMR RV EDVi (ml/m2) , per 1 SD 
CMR RV ESVi (ml/m2) , per 1 SD 
3.44 (1.89 – 6.24) 
0.97 (0.95 – 1.00) 
1.00 (0.99 – 1.01) 
2.09 (1.13 – 3.86) 
1.00 (0.99 – 1.00) 
1.00 (0.97 – 1.04) 
0.86 (0.60 – 1.24) 
1.11 (0.80 – 1.54) 
1.19  (0.84 – 
1.67) 
0.87 (0.63 – 1.19) 
0.62 (0.42 – 0.91) 
1.00 (0.68 – 1.49) 














3.53 (1.51 – 8.27) 
0.99 (0.96 – 1.02) 
 







0.35 (0.02 – 7.57) 
 















Legend: AF = atrial fibrillation, NT-pro BNP = N-terminal pro-brain natriuretic peptide, LGE = late gadolinium enhancement, CMR = 
cardiovascular magnetic resonance, ECHO = echocardiogram, LAVi = left atrial volume index, LVEF = left ventricular ejection fraction, 
RVEF = right ventricular ejection fraction, EDVi = end-diastolic volume index, ESVi = end-systolic volume index, SD=standard 
deviation.  

















Table 2b: Hazard ratios for LGE from univariate and multivariate Cox regression for each end point 
Outcome LGE Status Events 
Univariate Multivariate * 
HR (95% CI) p-value HR (95% CI) p-value 
MACE 
LGE + 30  
3.44 (1.89 – 6.24) p<0.001 3.53 (1.51 – 8.27) 0.004 
LGE - 17  
Heart Failure 
Rehospitalisations 
LGE + 19  
2.89 (1.42 – 5.85) 0.003 3.07 (1.24 – 7.59) 0.015 
LGE - 13  
Ventricular Arrhythmia Events 
LGE + 9  
8.48 (1.81 – 39.72) 0.007 4.88 (0.39 – 60.54) 0.217 
LGE - 2  
Cardiac Death 
LGE + 2  
2.01 (0.28 – 14.31) 0.484 2.69 (0.17 – 42.55) 0.482 
LGE - 2  
 
Legend: LGE = late gadolinium enhancement, LGE + = LGE positive, LGE - = LGE negative 
* Adjusted for age, atrial fibrillation, cardiovascular magnetic resonance right ventricular ejection fraction (CMR RVEF), CMR RV end-


















Most CMR trials have demonstrated the poor prognostic outcomes of myocardial fibrosis in 
established NIDCM. This is the first study to have demonstrated the presence of myocardial 
replacement in patients at first presentation NIDCM is independently associated with increased 
HF events. This may warrant a more proactive approach to medical therapy in patients who are 
at risk of HF or with asymptomatic left ventricular dysfunction where the syndrome of chronic 
HF has yet to evolve. 
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